下一代肿瘤不可知靶点即将出现
Next-generation tumor-agnostic targets on the horizon.
肿瘤不可知药物开发将肿瘤学重新聚焦于共享的分子依赖性而非组织来源,从而能够针对跨肿瘤的罕见可操作驱动因素进行高效开发。
英文原题:Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy.
Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy.
骨肉瘤(OS)是一种侵袭性恶性骨肿瘤,治疗选择有限,对免疫治疗反应率低。
骨肉瘤(OS)是一种侵袭性恶性骨肿瘤,治疗选择有限,对免疫治疗反应率低。OS的罕见性减缓了临床转化,凸显了建立连接患者来源异种移植(PDX)系统与下一代平台的模型的必要性。在此,我们通过将单细胞悬液自组装为个体化OS类器官(iOS),建立了一个OS PDX-类器官交互式生物样本库。iOS模型在体外以毫米级尺度重现了OS的空间和结构特征,作为异种移植物时亦然,并与匹配的PDX模型保持功能性配对。我们利用组织病理学、空间特征、基因组学、转录组学和药物基因组学验证了iOS的保真度。通过在PDX来源的iOS模型中重建T细胞浸润,我们模拟了治疗相关免疫反应,并支持免疫治疗转化研究。利用配对的iOS-PDX模型,我们证明一种PRMT5 MTA抑制剂可增强染色体9p21.3缺失型OS的免疫治疗反应。
Osteosarcoma (OS) is an aggressive malignant bone tumor with limited therapeutic options and low response to immunotherapy. OS rarity slows clinical translation, highlighting the need for models that bridge patient-derived xenograft (PDX) systems and next-generation platforms. Here, we establish an OS PDX-organoid interactive biobank by self-assembling single-cell suspensions into individualized OS organoids (iOSs). iOS models recapitulate OS spatial and architectural features at millimeter scale in vitro and as xenografts and maintain functional pairing with matched PDX models. We validate iOS fidelity using histopathology, spatial features, genomics, transcriptomics, and pharmacogenomics. By reconstructing T cell infiltration in PDX-derived iOS models, we model treatment-associated immune responses and support immunotherapy translational studies. Using paired iOS-PDX models, we show that a PRMT5 MTA inhibitor enhances immunotherapy response in chromosome 9p21.3-deleted OS.
MEMBER ACCOUNT
登录成功会直接打开下一页。